DAE HWA PHARM (067080) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, DAE HWA PHARM (067080) reported revenue of 143.1 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025143.1 billion KRW3.2 billion KRW2.3 billion KRW[source]
2024149.4 billion KRW6.7 billion KRW830 million KRW[source]
2023141.4 billion KRW2.0 billion KRW-514 million KRW[source]
2022131.9 billion KRW5.8 billion KRW1.2 billion KRW[source]
2021117.2 billion KRW3.3 billion KRW2.0 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025191.2 billion KRW118.3 billion KRW72.9 billion KRW[source]
2024188.3 billion KRW116.0 billion KRW72.2 billion KRW[source]
2023201.8 billion KRW125.3 billion KRW76.5 billion KRW[source]
2022182.6 billion KRW99.0 billion KRW83.6 billion KRW[source]
2021158.6 billion KRW74.8 billion KRW83.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice